Thera-SAbDab

DUPILUMAB

>   Structural Summary
TherapeuticDupilumab
TargetIL4R
Heavy ChainEVQLVESGGGLEQPGGSLRLSCAGSGFTFRDYAMTWVRQAPGKGLEWVSSISGSGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDRLSITIRPRYYGLDVWGQGTTVTVSS
Light ChainDIVMTQSPLSLPVTPGEPASISCRSSQSLLYSIGYNYLDWYLQKSGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGFYYCMQALQTPYTFGQGTKLEIK
100% seqID Fv Structure6wg8 [Fvs: AB], 6wgb [Fvs: AB, CD], 6wgj [Fvs: AB, CD, EF], 6wgk [Fvs: AB, CD, EF, GH], 6wgl [Fvs: AB]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG4
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental TechnologyVelocImmune Mouse
INN Year Proposed2012
INN Year Recommended2013
Companies InvolvedAimmune Therapeutics, Regeneron Pharmaceuticals, Sanofi
Conditions ApprovedAsthma, Atopic dermatitis
Conditions ActiveNasal polyps, Chronic obstructive pulmonary disease, Eosinophilic oesophagitis, Grass pollen hypersensitivity, Peanut hypersensitivity, Urticaria, Allergic asthma
Conditions Discontinuedna
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]